首页> 美国卫生研究院文献>Arthritis Research >Peroxisome proliferator-activated receptor γ1 expression is diminished in human osteoarthritic cartilage and is downregulated by interleukin-1β in articular chondrocytes
【2h】

Peroxisome proliferator-activated receptor γ1 expression is diminished in human osteoarthritic cartilage and is downregulated by interleukin-1β in articular chondrocytes

机译:过氧化物酶体增殖物激活受体γ1在人骨关节炎软骨中减少并在关节软骨细胞中被白介素-1β下调

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Peroxisome proliferator-activated receptor γ (PPARγ) is a nuclear receptor involved in the regulation of many cellular processes. We and others have previously shown that PPARγ activators display anti-inflammatory and chondroprotective properties in vitro and improve the clinical course and histopathological features in an experimental animal model of osteoarthritis (OA). However, the expression and regulation of PPARγ expression in cartilage are poorly defined. This study was undertaken to investigate the quantitative expression and distribution of PPARγ in normal and OA cartilage and to evaluate the effect of IL-1β, a prominent cytokine in OA, on PPARγ expression in cultured chondrocytes. Immunohistochemical analysis revealed that the levels of PPARγ protein expression were significantly lower in OA cartilage than in normal cartilage. Using real-time RT-PCR, we demonstrated that PPARγ1 mRNA levels were about 10-fold higher than PPARγ2 mRNA levels, and that only PPARγ1 was differentially expressed: its levels in OA cartilage was 2.4-fold lower than in normal cartilage (p < 0.001). IL-1 treatment of OA chondrocytes downregulated PPARγ1 expression in a dose- and time-dependent manner. This effect probably occurred at the transcriptional level, because IL-1 decreases both PPARγ1 mRNA expression and PPARγ1 promoter activity. TNF-α, IL-17, and prostaglandin E2 (PGE2), which are involved in the pathogenesis of OA, also downregulated PPARγ1 expression. Specific inhibitors of the mitogen-activated protein kinases (MAPKs) p38 (SB203580) and c-Jun N-terminal kinase (SP600125), but not of extracellular signal-regulated kinase (PD98059), prevented IL-1-induced downregulation of PPARγ1 expression. Similarly, inhibitors of NF-κB signaling (pyrrolidine dithiocarbamate, MG-132, and SN-50) abolished the suppressive effect of IL-1. Thus, our study demonstrated that PPARγ1 is downregulated in OA cartilage. The pro-inflammatory cytokine IL-1 may be responsible for this downregulation via a mechanism involving activation of the MAPKs (p38 and JNK) and NF-κB signaling pathways. The IL-1-induced downregulation of PPARγ expression might be a new and additional important process by which IL-1 promotes articular inflammation and cartilage degradation.
机译:过氧化物酶体增殖物激活受体γ(PPARγ)是参与许多细胞过程调节的核受体。我们和其他人先前已经证明,PPARγ活化剂在体外显示抗炎和软骨保护特性,并在骨关节炎(OA)的实验动物模型中改善其临床进程和组织病理学特征。然而,软骨中PPARγ表达的表达和调控尚不清楚。这项研究旨在研究PPARγ在正常和OA软骨中的定量表达和分布,并评估OA中重要的细胞因子IL-1β对培养的软骨细胞中PPARγ表达的影响。免疫组织化学分析显示,OA软骨中PPARγ蛋白的表达水平明显低于正常软骨。使用实时RT-PCR,我们证明PPARγ1mRNA水平比PPARγ2mRNA水平高约10倍,并且只有PPARγ1被差异表达:其OA软骨水平比正常软骨低2.4倍(p < 0.001)。 IL-1治疗OA软骨细胞以剂量和时间依赖性方式下调PPARγ1表达。这种作用可能发生在转录水平,因为IL-1降低了PPARγ1mRNA表达和PPARγ1启动子活性。参与OA发病的TNF-α,IL-17和前列腺素E2(PGE2)也下调了PPARγ1的表达。有丝分裂原活化蛋白激酶(MAPKs)p38(SB203580)和c-Jun N端激酶(SP600125)的特异性抑制剂可阻止IL-1诱导的PPARγ1表达下调,但不能抑制细胞外信号调节激酶(PD98059)。 。同样,NF-κB信号抑制剂(吡咯烷二硫代氨基甲酸酯,MG-132和SN-50)消除了IL-1的抑制作用。因此,我们的研究表明OA软骨中PPARγ1被下调。促炎细胞因子IL-1可能通过涉及MAPKs(p38和JNK)和NF-κB信号通路激活的机制来导致这种下调。 IL-1诱导的PPARγ表达下调可能是IL-1促进关节炎症和软骨降解的新的重要过程。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号